Worth reading
78Important
Scored from 2 of 6 sectionsDirection
Improvement
Direction inferred from the company’s description.Scale
9984
¥ millions (year-on-year change in operating income)Wording
Conditional
How definitive the wording is.Contents of this document
Supplementary Materials to the Earnings ReportFiscal year ending March 2027, second quarter (first half)6 items taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥48,957 million+24.4%
Operating profit¥10,164 million
Ordinary income¥10,708 million
Net income¥8,000 million+698.1%
Gross Profit Margin62.9 %
Operating profit margin20.8 %
Selling, general and administrative expenses¥20,645 million
Full-year earnings forecast
Net Sales
¥89,900 million
Operating profit
¥7,900 million
Ordinary income
¥8,600 million
Profit attributable to owners of the parent
¥6,500 million
What the company explained in this material
Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.
Average exchange rate (per US$1)
Actual results¥160.48
Plan¥145
New initiatives
- KAR (head lice infestation): application in Japan for marketing approval
- KP-001 (refractory vascular malformations): application in Japan for marketing approval
- Preparation for the launch of the silk elastin wound-care sheet
Key KPIsA metric the company considers important as a management benchmark.
- Overseas revenue¥18,245 millionYear on year against the same period last year+254.8%
- Overseas revenue ratio37.3 %
- Average exchange rate (per US$1)¥160.48
- Capital expenditures¥1,808 millionYear on year against the same period last year-17.6%
- Depreciation and Amortization¥1,883 millionYear on year against the same period last year+34.5%
- Number of employees1,162 PeopleYear on year against the same period last year+2.7%
Segment results
Pharmaceuticals
Net Sales
¥47,640 million+25.1%
Pharmaceuticals and medical devices (Japan and overseas)
Net Sales
¥45,056 million+26.0%
Agricultural chemicals
Net Sales
¥2,504 million+12.9%
Other
Net Sales
¥79 million-13.1%
Real Estate Business
Net Sales
¥1,317 million+3.4%
Number of employees
Number of Employees1,162
Change during the period30
Capital expenditures
¥1,808 million
| Item | Details |
|---|---|
| Document type | Supplementary Materials to the Earnings Report |
| Fiscal Period Covered | Fiscal year ending March 2027, second quarter (first half) |
| Net Sales | ¥48,957 million (YoY +24.4%) |
| Operating profit | ¥10,164 million |
| Ordinary income | ¥10,708 million |
| Net income | ¥8,000 million (YoY +698.1%) |
| Gross Profit Margin | 62.9 % |
| Operating profit margin | 20.8 % |
| Selling, general and administrative expenses | ¥20,645 million |
| Full-year earnings forecast | Net Sales ¥89,900 million / Operating profit ¥7,900 million / Ordinary income ¥8,600 million / Profit attributable to owners of the parent ¥6,500 million |
| Segment results | Pharmaceuticals Net Sales ¥47,640 million (YoY +25.1%) / Pharmaceuticals and medical devices (Japan and overseas) Net Sales ¥45,056 million (YoY +26.0%) / Agricultural chemicals Net Sales ¥2,504 million (YoY +12.9%) / Other Net Sales ¥79 million (YoY -13.1%) / Real Estate Business Net Sales ¥1,317 million (YoY +3.4%) |
| Key KPIs | Indicator name Overseas revenue / Value ¥18,245 million / Year on year against the same period last year ¥254.8 million, Indicator name Overseas revenue ratio / Value 37.3 % / Year on year against the same period last year Not disclosed, Indicator name Average exchange rate (per US$1) / Value ¥160.48 / Year on year against the same period last year Not disclosed, Indicator name Capital expenditures / Value ¥1,808 million / Year on year against the same period last year ¥-17.6 million, Indicator name Depreciation and Amortization / Value ¥1,883 million / Year on year against the same period last year ¥34.5 million, Indicator name Number of employees / Value 1,162 People / Year on year against the same period last year 2.7 People |
| Number of employees | Number of Employees 1,162 / Change during the period 30 / Hiring plan Not disclosed |
| Assumptions Underlying the Business Outlook | Average exchange rate (per US$1) Actual results ¥160.48 / Plan ¥145 |
| Capital expenditures | ¥1,808 million |
| New initiatives | KAR (head lice infestation): application in Japan for marketing approval, KP-001 (refractory vascular malformations): application in Japan for marketing approval, Preparation for the launch of the silk elastin wound-care sheet |
Items this document does not state (15)
Results for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planBreakdown of Factors Affecting the ChangeUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.There is no narrative explanation of the factors behind the changes. In numerical terms, sales of pharmaceuticals and medical devices and overseas sales, particularly overseas pharmaceutical sales, increased significantly, while selling, general and administrative expenses and research and development expenses declined.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.